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Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term 
“Neurotoxic syndrome” can be used when a clear distinction cannot be made between the two. Here we present 
a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive 
neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly 
induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this 
problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
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CASE REPORT
Neuroleptic malignant syndrome (NMS), one of 
the most serious and unexpected adverse reactions 
after taking neuroleptics, is characterized by a clinical 
triad of altered mental status, dysautonomia, and 
muscle rigidity.
1 The diagnosis is established on charac-
teristic clinical features in the setting of exposure to 
a neuroleptic.
1 Although haloperidol has been involved 
in many of published cases of NMS, virtually all 
classes of D2 receptor antagonist can produce NMS, 
including prochloroperazine, metoclopramide, droperidol, 
promethazine, and so on.
2
Serotonin syndrome is associated with excessive 
stimulation of 5-HT2a and 5-HT1a receptors. Clinically, it 
is characterized by a triad of mental status changes, 
autonomic hyperactivity, and neuromuscular abnorma-
lities.
3 It may appear after administration of drugs 
modulating serotonergic neurotransmission, such as  
monoamine oxidase inhibitors, tricyclic antidepressants, 
selective serotonin-reuptake inhibitors (SSRIs), opiate 
analgesics, over-the-counter cough medicines, antibiotics, 
antiemetics, antimigraine agents, and herbal products.
4 
The incidence of serotonin syndrome increases due to 
increasing use of proserotonergic agents in recent clinical 
practice.
3
Since NMS and serotonin syndrome share many 
clinical features in common, it may be difficult to 
separate the two syndromes clearly, particularly when a Journal of Clinical Neurology: Vol. 3, No. 3, 2007
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subject is exposed to both classes of drugs.
5 Therefore, 
the term “Neurotoxic syndrome” has been used when a 
clear distinction cannot be made between the two 
conditions.
5 Here we present a case of 19-year-old 
man who experienced serotonin syndrome caused by 
sertraline, and then NMS by risperidone.
CLINICAL HISTORY
A nineteen year-old man was admitted to our hospital 
because of drowsiness and fever. Ten days prior to 
admission, he had an upper respiratory infection, and 
started to take medications including 50 mg/d of 
sertraline for depression. Two days later, he became 
delirious and agitated, having difficulty in swallowing, 
and was brought to a local hospital. He showed 
tachycardia, tachypnea, hyperthermia, diaphoresis and 
increased bowel sound. His pupil size was normal. He 
showed agitation, with hyperreflexia in both upper 
extremities, and increased muscle tone in both lower 
extremities. Sertraline and all other medications were 
withdrawn.  Risperidone 1 mg/d was newly started for 
agitation. Three days later, h e  s h o w e d  m o r e  s e v e r e  
muscle rigidity and intermittent myoclonic jerks in 
all limbs without improvement of initial symptoms. 
Subsequently, he was referred to our hospital.
He was born with no perinatal problems. He 
developed a febrile seizure when he was 2 years old. 
Subsequently, he showed mental retardation with 
occasional aggressive behavior. He was able to walk 
by himself, and communicate with others verbally. He 
was educated at a specialized educational institute. 
He was on regular medication: quetiapine (200 mg/d), 
benztropine (2 mg/d), propranolol (80 mg/d), and clona-
zepam (1.5 mg/d)] to control his aggressive behavior.
On admission, he appeared acutely ill. His systolic 
blood pressure was 170 mmHg, his heart rate, 170 
per minute, temperature, 37.8℃ Bowel sound was 
not increased. He was drowsy with spontaneous eye 
opening and localizing response to painful stimuli. 
He was unable to follow verbal commands, and there 
was no verbal output. Pupil sizes, light reflexes, and 
external ocular movements were normal. There was 
no motor weakness. Responses to painful stimuli were 
symmetric. He showed marked rigidity with intermittent 
myoclonic jerks in all extremities. Throat examination 
showed tonsilar exudates with pharyngeal injection. 
WBC count increased to 15600 x 10
3/μl, (segmented 
neutrophils: 67.5%, lymphocytes: 18.7%, monocytes: 
13.5%). Serum electrolytes were normal, while muscle 
enzyme increased (CK=7744 IU/L). Brain CT, electro-
encephalography and cerebrospinal fluid studies were 
all normal.
Ampicillin/sulbactam was started intravenously for 
tonsilar infection. At the first night of hospitalization, 
he experienced two episodes of generalized tonic 
clonic seizure, each lasting for 3 minutes. In suspect 
of serotonin syndrome by sertraline or NMS by 
risperidone, we discontinued all medications he was 
taking, and started bromocriptine (15 mg/d), L-dopa/ 
carbidopa (300/75 mg/d), and dantrolene (50 mg/d) 
from the second hospital day. Right after medication 
changes, he showed dramatic improvement in drow-
siness, myoclonic jerks and muscle rigidity. On day 3, 
we added clonazepam (1.5 mg/d) and tapered down 
datrolene, bromocriptine, and L-dopa/carbidopa slowly. 
On day 5, he became more alert with no myoclonic jerks. 
On day 7, he was discharged home with quetiapine 200 
mg/d and clonazepam 1.5 mg/d for aggressive behavior.
DISCUSSION
We believe that this 19-year-old man experienced 
drug-induced neurotoxic syndrome: in particular, sero-
tonin syndrome by sertraline, and NMS by risperidone.
Our patient showed mental state change, autonomic 
hyperactivity, and neuromuscular abnormalities, which 
are well known symptoms of both serotonin syndrome 
and NMS.
1,4
The diagnosis of NMS is supported by hyperthermia, 
rigidity, elevated muscle enzyme and symptomatic 
improvement with bromocriptine and dantrolene.
1  On 
the other hand, the initial signs of agitation, diaphoresis, 
increased bowel sound, and myoclonus favor the 
diagnosis of serotonin syndrome.
4 It is likely that he 
had experienced serotonin syndrome induced by Kim JM, et al. Neurotoxic Syndrome by Sertraline and Risperidone
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sertraline, and then, NMS by risperidone. SSRI are 
associated not only with serotonin syndrome, but also 
with NMS or neurotoxic syndrome.
9 The proposed 
theory concerning extrapyramidal reactions occurring 
in SSRI involves the inhibitory effects of serotonin 
on dopamine activity.
9 
Differential diagnosis between NMS and serotonin 
syndrome is important to treat suspected patients 
because treatment strategies are different. NMS is 
considered as an idiosyncratic reaction to neuroleptic 
medication, whereas serotonin syndrome is due to 
the excessive serotonergicactivity, so dose dependent 
risk increase may be more prominent in serotonin 
syndrome than NMS.
5 Clincians’ awareness of these 
syndromes and high suspicion are necessary for the 
early diagnosis and management.
1,4 Both syndromes 
need immediate discontinuation of offending agents, 
vital sign monitoring, hydration, and general supportive 
care.
1,4 In NMS, dantrolen and bromocriptine can be 
used to moderate to severe cases, but bromocriptine 
is known to increase CNS serotonin, so may not be 
used in overlap cases.
6  
The reason why this patient developed both serotonin 
syndrome and NMS within a short period of time 
remains to be explained. Several mechanisms may 
explain this phenomenon, such as innate susceptibility 
to CNS acting drugs, the co-administration of drugs 
that interact on several CNS neurotransmitter-receptor 
systems simultaneously (i.e. SSRI), and the presence of 
underlying medical conditions, for example, underlying 
mental retardation. Several drug interactions have been 
known to cause serotonin syndrome; phenelzine and 
meperidine, paroxetine and buspirone, linezolide and 
citalopram, etc.
4 In addition, several single agents can 
induce serotonin syndrome, and sertraline is one of 
the well-known examples.
4 In the present case, we 
regarded the initial episode as serotonin syndrome 
caused by sertraline alone and the latter as NMS by 
risperidone. His previous medications, such as valproate, 
quetiapine or clonazepam might have aggravated 
serotonin syndrome or NMS by drug interaction. For 
example, quetiapine alone may cause NMS in sus-
ceptible patients, although it is known to be more 
tolerable than risperidone.
10,11 However, there exists little 
evidence to prove the drug interaction. There have been 
serial cases of neurotoxic syndrome which were unable 
to be distinguished from NMS or serotonin syndrome.
5,7,8 
This is the first report of a neurotoxic syndrome 
developed serially in the same patient. We propose 
that there may be cross-over susceptibility between 
the two syndromes, and thus, clinicians should be 
careful when prescribing drugs to patients who have 
already developed one of neurotoxic syndrome.
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